All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Axatilimab for cGvHD: Results from the phase II AGAVE-201 trial
By Ella Dixon
Bookmark this article
|
CSF-1 is a key mediator of inflammation and fibrosis; therefore, inhibiting CSF-1 can reduce the symptoms of cGvHD. Axatilimab is an IgG4 monoclonal antibody that inhibits CSF-1 signaling. The phase II multinational, randomized AGAVE-201 trial evaluated three doses of axatilimab in 241 patients aged ≥2 years with recurrent/refractory cGvHD:
The primary endpoint was overall response in the first six treatment cycles. The key secondary endpoint was patient-reported decrease in cGvHD symptom burden, with safety also assessed.
|
| Key learnings: |
|
The primary endpoint was met across all dose groups, with response rates of 74% (95% CI, 63–83), 67% (95% CI, 55–77), and 50% (95% CI, 39–61) for the 0.3 mg, 1 mg, and 3 mg groups, respectively. |
|
A clinically meaningful reduction in cGvHD symptoms, as measured by >5 point reduction in the modified Lee Symptom Scale, was observed in 60%, 69%, and 41% of patients in the 0.3 mg, 1 mg, and 3 mg groups, respectively. |
|
The most common adverse events included dose-dependent transient laboratory abnormalities (≤62%), associated with CSF1 inhibition, and periorbital edema (3–29%). Higher doses led to more frequent discontinuations due to adverse events (6% for 0.3 mg, 22% for 1 mg, and 18% for 3 mg doses). |
|
Axatilimab therefore shows promise as a new therapeutic option for cGvHD, particularly for patients refractory to prior lines of therapy, in addition to improving symptom control and reducing steroid dependence. |
Abbreviations: cGvHD, chronic graft-versus-host disease; CSF-1, colony stimulating factor-1; CI, confidence interval.
- Wolff D, Cutler C, Lee SJ, et al. Axatilimab in recurrent or refractory chronic graft-versus-host disease. N Engl J Med. 2024;391(11):1002-1014. DOI: 10.1056/NEJMoa2401537
More about...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox